Merck & Co., Inc. (BMV:MRK)

Market Cap	4.47T
Revenue (ttm)	1.34T
Net Income (ttm)	356.67B
Shares Out	n/a
EPS (ttm)	140.44
PE Ratio	12.54
Forward PE	n/a
Dividend	61.45 (3.40%)
Ex-Dividend Date	Mar 17, 2025

Volume	233
Average Volume	6,947
Open	1,768.40
Previous Close	1,763.83
Day's Range	1,755.05 - 1,771.00
52-Week Range	1,658.09 - 2,488.00
Beta	0.36
RSI	39.32
Earnings Date	Apr 24, 2025

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1891
• Employees: 75,000
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: MRK

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD